Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
7 Trends Drug Investors Should Know
Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE
7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...